TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Joint ( (JYNT) ).
On November 2, 2025, The Joint Corp. entered into an Asset Purchase Agreement with Elite Chiro Group to sell the assets of 45 clinics in Southern California for $4.5 million. This transaction includes franchise rights and is subject to certain conditions, including lease assignments and customary closing conditions. Additionally, The Joint Corp. has been authorized to repurchase an additional $12 million of its stock, reflecting confidence in its growth and profitability strategies. The company reported a 6% revenue increase in Q3 2025 compared to Q3 2024, with significant improvements in net income and adjusted EBITDA, despite a slight decline in system-wide sales.
The most recent analyst rating on (JYNT) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.
Spark’s Take on JYNT Stock
According to Spark, TipRanks’ AI Analyst, JYNT is a Neutral.
The overall stock score is primarily influenced by financial performance and technical analysis. The company faces significant profitability and cash flow challenges, reflected in its negative P/E ratio and bearish technical indicators. Despite some positive developments in the earnings call, such as EBITDA growth and refranchising efforts, the stock’s valuation and technical outlook remain weak.
To see Spark’s full report on JYNT stock, click here.
More about Joint
The Joint Corp. is a national operator, manager, and franchisor of chiropractic clinics, focusing on providing chiropractic care through its network of company-owned and franchised clinics.
Average Trading Volume: 88,376
Technical Sentiment Signal: Sell
Current Market Cap: $121.1M
Learn more about JYNT stock on TipRanks’ Stock Analysis page.